AIM — AIM ImmunoTech Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 946644 ·
Last close
$0.25
Market Cap
$6.93M
52W High
$1.25
52W Low
$0.21
ADV30
1,026,330
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,000 | 18,000 | -2,226,000 | -3,023,000 | 8,585,000 | 5,816,000 | 6,460,000 |
| Dec 2025 | 21,000 | -19,000 | -2,952,000 | -4,175,000 | 5,782,000 | 2,985,000 | 15,565,000 |
| Sep 2025 | 26,000 | -42,000 | -2,447,000 | -3,284,000 | 5,494,000 | 2,347,000 | 11,571,000 |
| Jun 2025 | 25,000 | 15,000 | -2,646,000 | -2,794,000 | 4,129,000 | 476,000 | 10,675,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,315,000
Investing CF
$918,000
Financing CF
$15,315,000
CapEx
$-413,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,809,000
Inventory
—
Receivables
$0
ST Investments
$63,000
EBIT TTM
$-12,284,000
Pretax Income TTM
$-13,276,000
Interest Exp TTM
$992,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$94,000
EBITDA
$-10,076,000
Free Cash Flow
$-12,225,375
Enterprise Value
$2,388,307
Total Cash
$5,879,000
Total Debt
$4,574,000
Shares Out
27,724,245
Trailing EPS
$-4.31
Book Value
$0.26
ROE
—
ROA
-86.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 88,000 | -11,664,000 | -13,958,000 | 5,782,000 | 15,565,000 | — | -10,957,000 |
| Dec 2024 | 170,000 | -19,772,000 | -17,320,000 | 8,608,000 | 9,930,000 | — | -14,888,000 |
| Dec 2023 | 202,000 | -31,916,000 | -28,962,000 | 19,381,000 | 9,147,000 | — | -21,267,000 |
| Dec 2022 | 141,000 | -19,923,000 | -19,445,000 | 40,488,000 | 2,020,000 | — | -16,108,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-15,925,000
OpCashFlow TTM
$0
Assets (Latest)
$29,440,000
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LIMN | Liminatus Pharma, Inc. | $6.37M | $0.10 | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.18M | $0.58 | — |
| BCAB | BioAtla, Inc. | $5.46M | $3.29 | — |
| ZEOX | Zeo ScientifiX, Inc. | $9.12M | $1.16 | — |
| CRIS | CURIS INC | $9.78M | $5.02 | — |
News headlines (Yahoo Finance, 1h cache)
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
2026-07-24 12:04 · Yahoo
Bet on 5 Top-Ranked Stocks With Rising P/E
2026-07-23 12:25 · Yahoo
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
2026-07-07 13:03 · Yahoo
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
2026-06-24 12:29 · Yahoo
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
2026-06-22 12:45 · Yahoo
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
2026-06-18 13:01 · Yahoo
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
2026-06-18 12:00 · Yahoo
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
2026-06-15 12:01 · Yahoo
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
2026-06-09 13:29 · Yahoo
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of P
2026-06-08 12:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.